URG101 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
226	間質性膀胱炎（ハンナ型）	2

226. 間質性膀胱炎（ハンナ型）

---

臨床試験数 : 145 /  薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02591199 (ClinicalTrials.gov)	September 2015	28/10/2015	Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome	Interstitial Cystitis;Bladder Pain Syndrome	Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin	Urigen	NULL	Terminated	18 Years	N/A	All	92	Phase 2	United States
2	NCT00517868 (ClinicalTrials.gov)	August 2007	15/8/2007	Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis	URG101 Pharmacodynamic and Safety Study: A Randomized, Double-blind, Placebo-controlled, Multi-center Cross-over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.	Painful Bladder Syndrome;Interstitial Cystitis	Drug: URG101;Drug: Placebo	Urigen	NULL	Completed	18 Years	N/A	All	28	Phase 2	United States